Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for cancer. Its lead program, ELVN-001, is designed to inhibit BCR-ABL for chronic myeloid leukemia, while the company also maintains earlier-stage research efforts such as HER2-directed work and other pipeline opportunities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead drug candidates being advanced through clinical development, primarily ELVN-001 and related oncology assets.
Earlier-stage small-molecule programs and target discovery efforts built around validated cancer biology.
Potential monetization of pipeline assets through licensing, collaboration, or other strategic alternatives.
Internal R&D activities, including chemistry, biology, clinical planning, and regulatory strategy.
Customers
Enliven does not currently sell approved products, so its near-term 'customers' are primarily clinical investigators, trial participants, regulators, and potential future licensing partners. If its programs succeed, the eventual buyers would be physicians, hospitals, and payers treating patients with chronic myeloid leukemia or other oncology indications.
Hospitals, investigators, CROs, and trial participants supporting development of ELVN-001 and other candidates.
FDA and comparable agencies that determine whether product candidates can advance and ultimately be approved.
Pharmaceutical companies that may license or co-develop ELVN-001, ELVN-002, or other assets.
Physicians, hospitals, and payers that would buy approved therapies for CML or other cancers.
Strategy
The company is focused on advancing ELVN-001 through clinical development with a precision-medicine approach built on validated oncology targets. It is also preserving optionality through earlier-stage programs and potential strategic alternatives for ELVN-002, while relying on external partners for manufacturing and development execution.
The company is substantially dependent on this lead asset for future value creation.
A second asset or broader pipeline reduces single-asset concentration risk.
Outsourcing manufacturing and development supports a lean cost structure.
Geography
Enliven is headquartered in Boulder, Colorado and operates as a U.S.-based development company. Its business is concentrated in the United States, but clinical development, manufacturing, and regulatory activities can extend to third-party CROs, CMOs, and potential foreign regulators as programs advance.
Risks
Enliven is an early-stage, single-lead-asset biotech with no approved products and no product revenue, so clinical and regulatory outcomes dominate its risk profile. Its business also depends on external vendors, capital markets access, and the ability to manage safety, efficacy, and product liability risks as programs progress.
- Single-asset dependence on ELVN-001Impact: HighLikelihood: High
If the lead program fails or is delayed, the company loses its main value driver.
Exposure: Clinical development and commercialization
- Ongoing losses and financing riskImpact: HighLikelihood: High
The company has no product sales and must fund R&D through external capital.
Exposure: Liquidity and dilution
- Clinical trial and regulatory failureImpact: HighLikelihood: Medium
Early data may not predict later-stage success or satisfy FDA/EMA requirements.
Exposure: Approval pathway
- Product liability and safety exposureImpact: MediumLikelihood: Medium
Therapeutic candidates can trigger claims, investigations, recalls, or restrictions.
Exposure: Clinical and future commercial use
- Third-party CRO/CMO dependenceImpact: MediumLikelihood: Medium
Delays or failures by vendors can disrupt timelines and increase costs.
Exposure: Development execution
Accounting
Judgemental itemsManagement must estimate unpaid CRO, CMO, and clinical vendor costs at period-end.
Impact: Can materially shift R&D expense between quarters
Equity awards are used to attract and retain scientific and clinical talent.
Impact: Affects operating loss and non-cash expense profile
The company disclosed operating lease obligations for its facility lease.
Impact: Creates right-of-use assets and lease liabilities
Coverage levels and claims exposure can affect future costs and contingencies.
Impact: May influence expense and disclosure of contingent liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Nuvalent, Inc.
Pharmaceutical Preparations
PMV Pharmaceuticals, Inc.
PMVP · Pharmaceutical Preparations
PMV Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule cancer therapies, with an emphasis on genomically defined tumors.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Alumis Inc
ALMS · Pharmaceutical Preparations
Prelude Therapeutics Inc
PRLD · Pharmaceutical Preparations
Last updated: 24/09/2026